{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:03:44Z","timestamp":1790363024332,"version":"4.1.0"},"reference-count":70,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2015,12,2]]},"DOI":"10.1586\/14737140.2015.1115725","type":"journal-article","created":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T17:24:41Z","timestamp":1447262681000},"page":"1389-1403","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":118,"title":["Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1\u2013derived oncolytic immunotherapy"],"prefix":"10.1586","volume":"15","author":[{"given":"Kevin J","family":"Harrington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Puzanov","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Randolph","family":"Hecht","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Szabo","sequence":"additional","affiliation":[{"name":",","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swami","family":"Murugappan","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard L","family":"Kaufman","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,12,3]]},"reference":[{"key":"e_1_3_4_2_1","volume-title":"Papers of special note have been highlighted as:","unstructured":"Papers of special note have been highlighted as:"},{"key":"e_1_3_4_3_1","volume-title":"\u2022 of interest","unstructured":"\u2022 of interest"},{"key":"e_1_3_4_4_1","volume-title":"\u2022\u2022 of considerable interest","unstructured":"\u2022\u2022 of considerable interest"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.153"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2035"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.967682"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S49494"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.2312"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-1518"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00046"},{"issue":"4","key":"e_1_3_4_13_1","first-page":"1493","article-title":"New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies","volume":"34","author":"Azijli K","year":"2014","unstructured":"Azijli K, Stelloo E, Peters GJ, et al. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Anticancer Res. 2014;34(4):1493\u20131505.","journal-title":"Anticancer Res"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S64979"},{"key":"e_1_3_4_15_1","unstructured":"Bristol-Myers Squibb Company. YERVOY\u00ae (ipilimumab) prescribing information. 2013."},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0376-z"},{"key":"e_1_3_4_19_1","unstructured":"Brystol-Myers Squibb Company. OPDIVO (nivolumab) prescribing information. 2014."},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428"},{"issue":"5","key":"e_1_3_4_24_1","doi-asserted-by":"crossref","first-page":"Abstract 5009","DOI":"10.1200\/jco.2014.32.15_suppl.5009","article-title":"Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial","volume":"32","author":"Motzer RJ","year":"2014","unstructured":"Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. J Clin Oncol. 2014;32(5S):Abstract 5009.","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_3_4_25_1","doi-asserted-by":"crossref","first-page":"Abstract 4504","DOI":"10.1200\/jco.2014.32.15_suppl.4504","article-title":"Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)","volume":"32","author":"Hammers HJ","year":"2014","unstructured":"Hammers HJ, Plimack ER, Infante JR, et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2014;32(5S):Abstract 4504.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-11"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0206"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4169-5"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1750"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00191"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2287"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700946"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800907780058907"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/156652321306140103224550"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301885"},{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(01)00618-0"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/VAAT.S12980"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.65"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206459"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0759"},{"key":"e_1_3_7_2_1","doi-asserted-by":"crossref","first-page":"Abstract e14546","DOI":"10.1200\/jco.2012.30.15_suppl.e14546","article-title":"Phase I dose-escalation study of talimogene laherparepvec (T-VEC) for advanced pancreatic cancer (ca)","volume":"30","author":"Chang KJ","year":"2012","unstructured":"Chang KJ, Senzer NN, Binmoeller K, et al. Phase I dose-escalation study of talimogene laherparepvec (T-VEC) for advanced pancreatic cancer (ca). J Clin Oncol. 2012;30(Suppl):Abstract e14546.","journal-title":"J Clin Oncol"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0196"},{"key":"e_1_3_8_2_1","unstructured":"PR Newswire. Amgen Press Release. 2011 [cited 2015 Aug 3]. Available from: http:\/\/wwwext.amgen.com\/media\/media_pr_detail.jsp?year=2011&releaseID=1590733."},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.3675"},{"key":"e_1_3_9_2_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0809-6"},{"issue":"4","key":"e_1_3_10_2_1","first-page":"Abstract 1059P","article-title":"Systemic benefit of GM-CSF-Encoding, oncolytic herpes virus (talimogene laherparepvec, T-VEC) in metastatic melanoma: phase II assessment","volume":"25","author":"Senzer NN","year":"2014","unstructured":"Senzer NN, Bedell C, Horvath S, et al. Systemic benefit of GM-CSF-Encoding, oncolytic herpes virus (talimogene laherparepvec, T-VEC) in metastatic melanoma: phase II assessment. Ann Oncol. 2014;25(Suppl 4):Abstract 1059P.","journal-title":"Ann Oncol"},{"key":"e_1_3_10_3_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.10.66"},{"key":"e_1_3_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.8.1614"},{"issue":"4","key":"e_1_3_10_5_1","first-page":"Abstract 1102P","article-title":"Results of the extension trial of OPTiM, a multicenter, randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs GM-CSF for unresected stage IIIB-IV melanoma","volume":"25","author":"Nemunaitis JJ","year":"2014","unstructured":"Nemunaitis JJ, Andtbacka RH, Ross M, et al. Results of the extension trial of OPTiM, a multicenter, randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs GM-CSF for unresected stage IIIB-IV melanoma. Ann Oncol. 2014;25(Suppl 4):Abstract 1102P.","journal-title":"Ann Oncol"},{"key":"e_1_3_10_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"issue":"5","key":"e_1_3_10_7_1","doi-asserted-by":"crossref","first-page":"Abstract 9026","DOI":"10.1200\/jco.2014.32.15_suppl.9026","article-title":"Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): results from a phase III trial in patients with stage IIIb-IV melanoma","volume":"32","author":"Ross MI","year":"2014","unstructured":"Ross MI, Andtbacka RHI, Puzanov I, et al. Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): results from a phase III trial in patients with stage IIIb-IV melanoma. J Clin Oncol. 2014;32(Suppl 5S):Abstract 9026.","journal-title":"J Clin Oncol"},{"key":"e_1_3_10_8_1","unstructured":"Andtbacka RHI Ross MI Delman K et al. Responses of injected and uninjected lesions to intralesional talimogene laherparepvec (T-VEC) in the OPTiM study and the contribution of surgery to response. Society of Surgical Oncology Annual Cancer Symposium; 2014 Mar 12\u201315; Phoenix AZ. Abstract 52."},{"key":"e_1_3_10_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-S3-P263"},{"key":"e_1_3_10_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4100"},{"key":"e_1_3_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2015.01.003"},{"key":"e_1_3_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3770"},{"issue":"5","key":"e_1_3_10_13_1","doi-asserted-by":"crossref","first-page":"Abstract 9029","DOI":"10.1200\/jco.2014.32.15_suppl.9029","article-title":"Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma","volume":"32","author":"Puzanov I","year":"2014","unstructured":"Puzanov I, Milhem MM, Andtbacka RHI, et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol. 2014;32(5s):Abstract 9029.","journal-title":"J Clin Oncol"},{"key":"e_1_3_10_14_1","doi-asserted-by":"crossref","first-page":"Abstract 9063","DOI":"10.1200\/jco.2015.33.15_suppl.9063","article-title":"Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma","volume":"33","author":"Puzanov I","year":"2015","unstructured":"Puzanov I, Milhem M, Andtbacka RHI, et al. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol. 2015;33(Suppl):Abstract 9063.","journal-title":"J Clin Oncol"},{"key":"e_1_3_10_15_1","unstructured":"FirstWord Pharma. Amgen Press Release. 2015 [cited 2015 Jun 24]. Available from: http:\/\/www.firstwordpharma.com\/node\/1288054?tsid=33"},{"key":"e_1_3_10_16_1","doi-asserted-by":"crossref","unstructured":"Piasecki J Le T Ponce R et al. Talimogene laherparepvec increases the anti-tumor efficacy of the anti-PD-1 immune checkpoint blockade. American Association of Cancer Research Annual Meeting; 2015 Apr 18\u201322; Pennsylvania PH; Abstract 258.","DOI":"10.1158\/1538-7445.AM2015-258"},{"key":"e_1_3_10_17_1","doi-asserted-by":"crossref","first-page":"Abstract 9063","DOI":"10.1200\/jco.2015.33.15_suppl.tps9081","article-title":"A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma","volume":"33","author":"Ribas A","year":"2015","unstructured":"Ribas A, Puzanov I, Gajewski TF, et al. A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma. J Clin Oncol. 2015;33(Suppl):Abstract 9063.","journal-title":"J Clin Oncol"},{"key":"e_1_3_10_18_1","unstructured":"PR Newswire. Amgen Press Release. 2015 [cited 2015 Jun 25]. Available from: http:\/\/www.amgen.com\/media\/media_pr_detail.jsp?releaseID=2054439."},{"key":"e_1_3_10_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00489"},{"issue":"12","key":"e_1_3_10_20_1","first-page":"1378","article-title":"Anti-GITR antibodies\u2013potential clinical applications for tumor immunotherapy","volume":"11","author":"Schaer DA","year":"2010","unstructured":"Schaer DA, Cohen AD, Wolchok JD. Anti-GITR antibodies\u2013potential clinical applications for tumor immunotherapy. Curr Opin Investig Drugs. 2010;11(12):1378\u20131386.","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_10_21_1","first-page":"Abstract TPS909","article-title":"Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB\/C and IVM1a melanoma (MEL) (NCT02211131)","volume":"33","author":"Andtbacka RHI","year":"2015","unstructured":"Andtbacka RHI, Chastain M, Li A, et al. Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB\/C and IVM1a melanoma (MEL) (NCT02211131). J Clin Oncol. 2015;33(Suppl):Abstract TPS9094.","journal-title":"J Clin Oncol"},{"key":"e_1_3_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2014.03.002"},{"key":"e_1_3_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.08.035"},{"key":"e_1_3_10_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-014-0040-2"},{"key":"e_1_3_10_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.1106"},{"key":"e_1_3_10_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0053"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14737140.2015.1115725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:35:57Z","timestamp":1770392157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14737140.2015.1115725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,2]]},"references-count":70,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12,2]]}},"alternative-id":["10.1586\/14737140.2015.1115725"],"URL":"https:\/\/doi.org\/10.1586\/14737140.2015.1115725","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-12-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}